Remy Sukhija
Keine laufenden Positionen mehr
Vermögen: - $ am 31.03.2024
Profil
Remy Sukhija worked as the Chief Executive Officer at ODH, Inc. from 2018 to 2019.
Prior to that, he was the Executive Director at Merganser Biotech Australia Pty Ltd.
in 2015-2016 and the Chief Operating Officer at Merganser Biotech, Inc. in the same period.
From 2017 to 2020, he served as the Senior Vice President-North America at Otsuka Pharmaceutical Development & Commercialization, Inc. Currently, he is the Chief Commercial Officer & Senior Vice President at Madrigal Pharmaceuticals, Inc. from 2020 to 2023.
Mr. Sukhija completed his undergraduate degree from the University of Akron.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.03.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Ehemalige bekannte Positionen von Remy Sukhija
| Unternehmen | Position | Ende |
|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. | Corporate Officer/Principal | 25.09.2023 |
Otsuka Pharmaceutical Development & Commercialization, Inc.
 Otsuka Pharmaceutical Development & Commercialization, Inc. Pharmaceuticals: MajorHealth Technology Part of Otsuka Holdings Co., Ltd., Otsuka Pharmaceutical Development & Commercialization, Inc. is a healthcare company that was founded in 2007. The private company is based in Princeton, NJ. The company is driven by their purpose and defined by their beliefs. | Corporate Officer/Principal | 01.03.2020 |
ODH, Inc.
 ODH, Inc. Medical/Nursing ServicesHealth Services Part of Otsuka Holdings Co., Ltd., ODH, Inc. is a healthcare technology company that provides insightful solutions through data and analytics to their clients and individuals they serve. The private company is based in Princeton, NJ. | Chief Executive Officer | 01.06.2019 |
Merganser Biotech, Inc.
 Merganser Biotech, Inc. BiotechnologyHealth Technology Merganser Biotech, Inc. engages in the development of of hepcidin mimetic peptides as new medicines for the treatment of hematological and iron overload diseases. The company was founded by Brian R. MacDonald and Gene Merutka in 2011 and is headquartered in Newtown Square, PA. | Chief Operating Officer | 01.12.2016 |
| Merganser Biotech Australia Pty Ltd. | Director/Board Member | 01.12.2016 |
Ausbildung von Remy Sukhija
| University of Akron | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| MADRIGAL PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka Pharmaceutical Development & Commercialization, Inc. Pharmaceuticals: MajorHealth Technology Part of Otsuka Holdings Co., Ltd., Otsuka Pharmaceutical Development & Commercialization, Inc. is a healthcare company that was founded in 2007. The private company is based in Princeton, NJ. The company is driven by their purpose and defined by their beliefs. | Health Technology |
ODH, Inc.
ODH, Inc. Medical/Nursing ServicesHealth Services Part of Otsuka Holdings Co., Ltd., ODH, Inc. is a healthcare technology company that provides insightful solutions through data and analytics to their clients and individuals they serve. The private company is based in Princeton, NJ. | Health Services |
| Merganser Biotech Australia Pty Ltd. | |
Merganser Biotech, Inc.
Merganser Biotech, Inc. BiotechnologyHealth Technology Merganser Biotech, Inc. engages in the development of of hepcidin mimetic peptides as new medicines for the treatment of hematological and iron overload diseases. The company was founded by Brian R. MacDonald and Gene Merutka in 2011 and is headquartered in Newtown Square, PA. | Health Technology |
